Showing results (71-80 of 282) with videos related to
Sort By:
Pageof 29
Parasitology|February 1, 1989
Histological examination of the cellular reactions around schistosomula of Schistosoma mansoni in the lungs of sublethally irradiated and unirradiated, immune and control ratsD A Vignali, S N Klaus, Q D Bickle, et al.Nature Reviews. Immunology|March 26, 2013
Type 1 diabetes: translating mechanistic observations into effective clinical outcomesKevan C Herold, Dario A A Vignali, Anne Cooke, et al.Trends in Cancer|November 27, 2024
Advances in LAG3 cancer immunotherapeuticsKieran Adam, Samuel C Butler, Creg J Workman, et al.Immunology|May 16, 2019
Intratumoral regulatory T cells: markers, subsets and their impact on anti-tumor immunityHiroshi Yano, Lawrence P Andrews, Creg J Workman, et al.Nature Methods|February 21, 2006
Rapid analysis of T-cell selection in vivo using T cell-receptor retrogenic miceJeff Holst, Kate M Vignali, Amanda R Burton, et al.European Journal of Immunology|July 1, 1993
Minute quantities of a single immunodominant foreign epitope are presented as large nested sets by major histocompatibility complex class II moleculesD A Vignali, R G Urban, R M Chicz, et al.Journal of Immunology (Baltimore, Md. : 1950)|December 4, 2008
Outgrowth of CD4low/negCD25+ T cells with suppressor function in CD4+CD25+ T cell cultures upon polyclonal stimulation ex vivoChristine Vogtenhuber, Matthew J O'Shaughnessy, Dario A A Vignali, et al.Journal of Immunology (Baltimore, Md. : 1950)|May 6, 2009
Regulatory T cell suppression is potentiated by target T cells in a cell contact, IL-35- and IL-10-dependent mannerLauren W Collison, Meenu R Pillai, Vandana Chaturvedi, et al.Immunological Reviews|March 5, 2017
LAG3 (CD223) as a cancer immunotherapy targetLawrence P Andrews, Ariel E Marciscano, Charles G Drake, et al.Vox Sanguinis|February 6, 1999
Erythropoiesis after therapy with recombinant human erythropoietin: a dose-response study in anemic cancer surgery patientsM Braga, L Gianotti, O Gentilini, et al.Pageof 29